Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 31

1.

Risk stratification strategy and assessment of disease progression in patients with pulmonary arterial hypertension: Updated Recommendations from the Cologne Consensus Conference 2018.

Leuchte HH, Ten Freyhaus H, Gall H, Halank M, Hoeper MM, Kaemmerer H, Kähler C, Riemekasten G, Ulrich S, Schwaiblmair M, Ewert R.

Int J Cardiol. 2018 Dec 1;272S:20-29. doi: 10.1016/j.ijcard.2018.08.084. Epub 2018 Sep 13. Review.

PMID:
30266353
2.

[Risk stratification and follow-up assessment of patients with pulmonary arterial hypertension: Recommendations of the Cologne Consensus Conference 2016].

Leuchte HH, Ten Freyhaus H, Gall H, Halank M, Hoeper MM, Kaemmerer H, Kähler C, Riemekasten G, Ulrich S, Schwaiblmair M, Ewert R.

Dtsch Med Wochenschr. 2016 Oct;141(S 01):S19-S25. Epub 2016 Oct 19. Review. German.

PMID:
27760446
3.

Late outcomes after acute pulmonary embolism: rationale and design of FOCUS, a prospective observational multicenter cohort study.

Konstantinides SV, Barco S, Rosenkranz S, Lankeit M, Held M, Gerhardt F, Bruch L, Ewert R, Faehling M, Freise J, Ghofrani HA, Grünig E, Halank M, Heydenreich N, Hoeper MM, Leuchte HH, Mayer E, Meyer FJ, Neurohr C, Opitz C, Pinto A, Seyfarth HJ, Wachter R, Zäpf B, Wilkens H, Binder H, Wild PS.

J Thromb Thrombolysis. 2016 Nov;42(4):600-9. doi: 10.1007/s11239-016-1415-7.

4.

Self-Report Daily Life Activity as a Prognostic Marker of Idiopathic Pulmonary Fibrosis.

Leuchte HH, Mernitz P, Baezner C, Baumgartner RA, von Wulffen W, Neurohr C, Behr J.

Respiration. 2015;90(6):460-7. doi: 10.1159/000441302. Epub 2015 Nov 27.

5.

Residual pulmonary vasodilative reserve predicts outcome in idiopathic pulmonary hypertension.

Leuchte HH, Baezner C, Baumgartner RA, Muehling O, Neurohr C, Behr J.

Heart. 2015 Jun;101(12):972-6. doi: 10.1136/heartjnl-2015-307529.

PMID:
26015441
6.

[Riociguat: stimulator of soluble guanylate-cyclase. New mode of action for the treatment of pulmonary arterial and non operable chronic thromboembolic pulmonary hypertension].

Leuchte HH, Behr J, Ewert R, Ghofrani HA, Grünig E, Halank M, Held M, Klose H, Rosenkranz S, Schermuly RT, Wilkens H, Hoeper MM.

Pneumologie. 2015 Mar;69(3):135-43. doi: 10.1055/s-0034-1391435. Epub 2015 Mar 6. Review. German.

7.

[Treatment goals of pulmonary hypertension].

McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, Palazzini M, Park MH, Tapson VF, Sitbon O.

Turk Kardiyol Dern Ars. 2014 Oct;42 Suppl 1:95-105. Turkish.

8.

Augmentation of the effects of vasoactive intestinal peptide aerosol on pulmonary hypertension via coapplication of a neutral endopeptidase 24.11 inhibitor.

Leuchte HH, Prechtl C, Callegari J, Meis T, Haziraj S, Bevec D, Behr J.

Am J Physiol Lung Cell Mol Physiol. 2015 Mar 15;308(6):L563-8. doi: 10.1152/ajplung.00317.2014. Epub 2015 Jan 16.

9.

[Targeted therapy of pulmonary arterial hypertension (PAH)].

Klose H, Opitz C, Bremer H, Ewert R, Bonderman D, Rosenkranz S, Seeger W, Schmeißer A, Harbaum L, Buerke M, Ghofrani HA, Borst MM, Leuchte HH, Lange TJ, Behr J, Ulrich S, Lang I, Olschewski H, Gall H, Kabitz HJ, Kleber FX, Held M, Hoeper MM, Grünig E.

Dtsch Med Wochenschr. 2014 Dec;139 Suppl 4:S142-50. doi: 10.1055/s-0034-1387489. Epub 2014 Dec 9. Review. German. No abstract available.

PMID:
25489684
10.

Haemodynamic changes in pulmonary hypertension in patients with interstitial lung disease treated with PDE-5 inhibitors.

Zimmermann GS, von Wulffen W, Huppmann P, Meis T, Ihle F, Geiseler J, Leuchte HH, Tufman A, Behr J, Neurohr C.

Respirology. 2014 Jul;19(5):700-6. doi: 10.1111/resp.12294. Epub 2014 Apr 3.

11.

Treatment goals of pulmonary hypertension.

McLaughlin VV, Gaine SP, Howard LS, Leuchte HH, Mathier MA, Mehta S, Palazzini M, Park MH, Tapson VF, Sitbon O.

J Am Coll Cardiol. 2013 Dec 24;62(25 Suppl):D73-81. doi: 10.1016/j.jacc.2013.10.034. Review.

12.

[Chylothorax in an 87-year-old patient].

Richter MJ, Baumgartner R, Leuchte HH.

Internist (Berl). 2013 Jan;54(1):105-9. doi: 10.1007/s00108-012-3158-7. German.

PMID:
23111591
13.

Acute hemodynamic responses to supplemental oxygen and their prognostic implications in pulmonary hypertension.

Leuchte HH, Baezner CJ, Baumgartner RA, Mernitz P, Neurohr C, Behr J.

Respiration. 2013;85(5):400-7. doi: 10.1159/000340009. Epub 2012 Oct 4.

14.

The potential of biomarkers in pulmonary arterial hypertension.

Cracowski JL, Leuchte HH.

Am J Cardiol. 2012 Sep 15;110(6 Suppl):32S-38S. doi: 10.1016/j.amjcard.2012.06.014. Review.

PMID:
22921030
15.

Riociguat for interstitial lung disease and pulmonary hypertension: a pilot trial.

Hoeper MM, Halank M, Wilkens H, Günther A, Weimann G, Gebert I, Leuchte HH, Behr J.

Eur Respir J. 2013 Apr;41(4):853-60. doi: 10.1183/09031936.00213911. Epub 2012 Aug 30.

16.

Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with Updated Commentary of the Cologne Consensus Conference 2011.

Grünig E, Barner A, Bell M, Claussen M, Dandel M, Dumitrescu D, Gorenflo M, Holt S, Kovacs G, Ley S, Meyer JF, Pabst S, Riemekasten G, Saur J, Schwaiblmair M, Seck C, Sinn L, Sorichter S, Winkler J, Leuchte HH.

Int J Cardiol. 2011 Dec;154 Suppl 1:S3-12. doi: 10.1016/S0167-5273(11)70488-0.

PMID:
22221971
17.

Pulmonary hypertension: Hemodynamic evaluation. Updated Recommendations of the Cologne Consensus Conference 2011.

Opitz CF, Blindt R, Blumberg F, Borst MM, Bruch L, Leuchte HH, Lichtblau M, Nagel C, Peters K, Rosenkranz S, Schranz D, Skowasch D, Tiede H, Weil J, Ewert R.

Int J Cardiol. 2011 Dec;154 Suppl 1:S13-9. doi: 10.1016/S0167-5273(11)70489-2.

PMID:
22221969
18.

[Right heart catheterization in pulmonary hypertension].

Rosenkranz S, Behr J, Ewert R, Ghofrani HA, Grünig E, Halank M, Hoeper MM, Leuchte HH, Olschewski H, Schmeisser A, Speich R, Wilkens H, Opitz CF.

Dtsch Med Wochenschr. 2011 Dec;136(50):2601-16; quiz 2617-20. doi: 10.1055/s-0031-1292858. Epub 2011 Dec 7. Review. German. No abstract available.

PMID:
22160954
19.

[Non-invasive diagnosis of pulmonary hypertension: ESC/ERS Guidelines with commentary of the Cologne Consensus Conference 2010].

Grünig E, Barner A, Bell M, Claussen M, Dandel M, Dumitrescu D, Gorenflo M, Holt S, Kovacs G, Ley S, Meyer JF, Pabst S, Riemekasten G, Saur J, Schwaiblmair M, Seck C, Sinn L, Sorichter S, Winkler J, Leuchte HH.

Dtsch Med Wochenschr. 2010 Oct;135 Suppl 3:S67-77. doi: 10.1055/s-0030-1263314. Epub 2010 Sep 22. German.

PMID:
20862623
20.

Preserved pulmonary vasodilative properties of aerosolized brain natriuretic peptide.

Leuchte HH, Michalek J, Soenmez O, Meis T, Haziraj S, Cavalli V, Bevec D, Behr J.

Pulm Pharmacol Ther. 2009 Dec;22(6):548-53. doi: 10.1016/j.pupt.2009.07.002. Epub 2009 Jul 29.

PMID:
19646544
21.

Inhalation of vasoactive intestinal peptide in pulmonary hypertension.

Leuchte HH, Baezner C, Baumgartner RA, Bevec D, Bacher G, Neurohr C, Behr J.

Eur Respir J. 2008 Nov;32(5):1289-94. doi: 10.1183/09031936.00050008.

22.

Inhalation of endothelin receptor blockers in pulmonary hypertension.

Leuchte HH, Meis T, El-Nounou M, Michalek J, Behr J.

Am J Physiol Lung Cell Mol Physiol. 2008 Apr;294(4):L772-7. doi: 10.1152/ajplung.00405.2007. Epub 2008 Feb 22.

23.

N-terminal pro-brain natriuretic peptide and renal insufficiency as predictors of mortality in pulmonary hypertension.

Leuchte HH, El Nounou M, Tuerpe JC, Hartmann B, Baumgartner RA, Vogeser M, Muehling O, Behr J.

Chest. 2007 Feb;131(2):402-9.

PMID:
17296640
24.

Brain natriuretic peptide is a prognostic parameter in chronic lung disease.

Leuchte HH, Baumgartner RA, Nounou ME, Vogeser M, Neurohr C, Trautnitz M, Behr J.

Am J Respir Crit Care Med. 2006 Apr 1;173(7):744-50. Epub 2006 Jan 13.

PMID:
16415273
25.

Characterization of brain natriuretic peptide in long-term follow-up of pulmonary arterial hypertension.

Leuchte HH, Holzapfel M, Baumgartner RA, Neurohr C, Vogeser M, Behr J.

Chest. 2005 Oct;128(4):2368-74.

PMID:
16236896
26.

Iloprost for idiopathic pulmonary arterial hypertension.

Leuchte HH, Behr J.

Expert Rev Cardiovasc Ther. 2005 Mar;3(2):215-23. Review.

PMID:
15853595
27.

Brain natriuretic peptide and exercise capacity in lung fibrosis and pulmonary hypertension.

Leuchte HH, Neurohr C, Baumgartner R, Holzapfel M, Giehrl W, Vogeser M, Behr J.

Am J Respir Crit Care Med. 2004 Aug 15;170(4):360-5. Epub 2004 Apr 15.

PMID:
15087298
28.

Clinical significance of brain natriuretic peptide in primary pulmonary hypertension.

Leuchte HH, Holzapfel M, Baumgartner RA, Ding I, Neurohr C, Vogeser M, Kolbe T, Schwaiblmair M, Behr J.

J Am Coll Cardiol. 2004 Mar 3;43(5):764-70.

29.

Hemodynamic response to sildenafil, nitric oxide, and iloprost in primary pulmonary hypertension.

Leuchte HH, Schwaiblmair M, Baumgartner RA, Neurohr CF, Kolbe T, Behr J.

Chest. 2004 Feb;125(2):580-6.

PMID:
14769741
30.

Treatment of severe pulmonary hypertension with inhaled iloprost.

Leuchte HH, Baumgartner RA, Behr J.

Ann Intern Med. 2003 Aug 19;139(4):306. No abstract available.

PMID:
12965995
31.

[Acute pulmonary embolism emergency. Confirming diagnosis, administering heparin, begin thrombolysis].

Leuchte HH, Behr J.

MMW Fortschr Med. 2003 May 15;145(20):39-43. German.

PMID:
12822229

Supplemental Content

Loading ...
Support Center